BTC iShares MSCI EAFE Growth ETF
Most Recent
Doubtful about Roche’s Bladder Cancer Treatment? Look at Studies
Roche (RHHBY) noted that Tecentriq was granted Breakthrough therapy designation for use in the treatment of NSCLC.